Alane P. Barnes - 01 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief Legal Officer
Signature
/s/ Alane P. Barnes
Issuer symbol
BCRX
Transactions as of
01 Dec 2025
Net transactions value
-$871,934
Form type
4
Filing time
03 Dec 2025, 18:40:53 UTC
Previous filing
23 Dec 2024
Next filing
16 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Barnes Alane P Chief Legal Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM /s/ Alane P. Barnes 03 Dec 2025 0001584348

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $293,033 +91,004 +22% $3.22 507,156 01 Dec 2025 Direct F1
transaction BCRX Common Stock Sale $646,511 -91,004 -18% $7.10 416,152 01 Dec 2025 Direct F1, F2
transaction BCRX Common Stock Sale $367,216 -50,906 -12% $7.21 365,246 02 Dec 2025 Direct F3
transaction BCRX Common Stock Sale $151,240 -19,770 -5.4% $7.65 345,476 03 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -91,004 -100% $0.000000 0 01 Dec 2025 Common Stock 91,004 $3.22 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.015 to $7.190. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.180 to $7.255. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The option grant became exercisable at the rate of 25.0% on each of the first, second, third, and fourth anniversaries of the date of grant.